Pioneering Advancements in the Pulmonary
senior management team and the Board of Directors have in-depth expertise
and experience in the management and oversight of public health care
companies and in bringing a variety of pharmaceutical and health care
products to market in the U.S.
and internationally. Members of the company's Scientific Advisory Board are
among the world's leading experts in pulmonary medicine and inhalation drug
delivery. Together, this leadership team is pioneering important
advancements in the respiratory sector of the pharmaceutical industry and
positioning Aradigm as a new leader in the specialty pharmaceutical market.
& Chief Executive Officer
Dr. Gonda has served as President and Chief Executive
Officer since August 2006, and as a director since September
2001. From December 2001 to August 2006, Dr. Gonda was
the Chief Executive Officer and Managing Director of Acrux
Limited, a publicly traded specialty pharmaceutical company
located in Melbourne, Australia.
From July 2001 to December 2001, Dr. Gonda was our Chief
Scientific Officer and, from October 1995 to July 2001,
was our Vice President, Research and Development. From
February 1992 to September 1995, Dr. Gonda was a Senior
Scientist and Group Leader at Genentech, Inc. leading
inhalation development of products for severe respiratory
disease. Prior to that, Dr. Gonda held academic positions
at the University of Aston in Birmingham, United Kingdom,
and the University of Sydney, Australia. Dr. Gonda holds
a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry
from Leeds University, United Kingdom.
Dr. Gonda was the Chairman of our Scientific Advisory
Board until August 2006.
Chief Financial Officer
Ms. Pecota has more than 20 years of experience in corporate
accounting and operations management. She previously served
as Chief Financial Officer for NuGEN Technologies, Inc.,
a life sciences tools company that provides specialty
reagents to pharmaceutical and diagnostics companies.
Prior to that she served as a financial consultant to
early- and mid-stage life sciences companies, developing
fundable business models and assessing and improving internal
financial preparation and reporting processes. She has
served as Vice President, Finance and Administration at
Signature BioScience, Inc., a venture-backed biopharmaceutical
company; and as Director, Finance and Accounting for ACLARA
BioSciences, Inc., a biotechnology company. Ms. Pecota
holds a Bachelor of Science in Economics from San
and was among the executives named in the San Francisco
Business Times "100 Most Influential Bay Area Business
Women" in 2002 and 2003.
Juergen Froehlich, MD, MBA, FCPh
Chief Medical Officer
Dr. Froehlich has more than 20 years of pharmaceutical
industry experience in preclinical, clinical and regulatory
activities at Boehringer Ingelheim, Genentech, Quintiles,
Bristol-Myers Squibb, Ipsen and Vertex Pharmaceuticals.
Dr. Froehlich was closely involved in the commercialization
of various drugs and biologics and alliance activities
with other companies. Dr. Froehlich graduated from the
Medical School at Wuerzburg University in Germany. He
is a Diplomate of the American Board of Clinical Pharmacology,
a Fellow of the American College of Clinical Pharmacology
and a Fellow of the Faculty of Pharmaceutical Medicine.
He also holds a dual executive MBA degree from the Graduate
School of Business Administration in Zurich, Switzerland
and from the State University of New York at Albany.
Robert A. Reed, Ph.D.
Vice President Regulatory CMC & Quality
Dr. Reed has more than 25+ years of industry experience
in chemistry, manufacturing and control (CMC) guiding API
development, drug product design and development,
pharmaceutical product and process characterization,
technology transfer and regulatory strategy and submissions,
including 12 years with liposomal products. He previously
served as Senior
Vice President of CMC and Technical Operations at
Celsion Corporation, Vice President of Pharmaceutical
Operations at XenoPort, Senior Director at Pharmaceutical
Research and Development at Merck and Company, and Research
Scientist at The Liposome Company.
While at Merck & Co., Dr.
Reed directed the CMC activities of many late stage
products, such as Crixivan®, Singulair® and Januvia®. At
XenoPort, Dr. Reed oversaw CMC activities for their lead
candidate, Horizant®. Overall, Dr. Reed has supported the
commercialization of 25 drugs for global registration. Dr.
Reed received his PhD from The University of North Carolina
at Chapel Hill, and was awarded a NIH Post Doctoral Fellow
at Princeton University.
He is an American Association of Pharmaceutical Scientists
Fellow and serves on the Industry Advisory Board to
University of the Pacific School of Pharmacy.
David Cipolla, Ph.D.
Vice President Preclinical R&D
Cipolla holds a chemical engineering degree from MIT (S.B.)
and UC Davis (M.S.) and a pharmacy degree from the
University of Sydney (Ph.D.). Dr. Cipolla currently leads
the preclinical research,
pharmaceutical sciences and intellectual property efforts at
Aradigm Corp and has served in various scientific and
technical capacities at Aradigm since 1996.
Prior to joining Aradigm, Dr. Cipolla worked at
Genentech, Inc. (1988-1996) developing and characterizing
the delivery of protein aerosols to the airways, culminating
with the approval of Pulmozyme® rhDNase for the management
of cystic fibrosis. Dr.
Cipolla has contributed in a number of roles on
pharmaceutical consortia (including chair of IPAC-RS),
academic societies (ISAM board member) and on the editorial
board of multiple scientific journals.
Janice Dahms, M.S.
Vice President Project Management
Ms. Dahms has more than 25 years of industry experience in
product development and project, portfolio and alliance
management. Prior to joining Aradigm, she served as
Executive Director of Product Development at Intarcia
Therapeutics, Senior Director of Project Management at
Abgenix, and held project management and clinical operations
positions at ALZA, PAREXEL and Bristol-Myers Squibb. She has
experience leading projects from early through late stages
of development and played a key role in the approval of 6
marketed products. Ms. Dahms built the project management
organizations at Intarcia and Abgenix to address their
individual needs which included oversight of outsourced
work, interfaces with development partners and evaluation of
potential new projects. Ms. Dahms is a graduate of Boston
University and earned her M.S. in Pharmacology from the
University of Chicago.
Board of Directors
Virgil D. Thompson
Chairman of the Board, Aradigm Corporation;
CEO of Spinnaker Biosciences, Inc.
President & Chief Executive Officer, Aradigm Corporation
Dr. John M. Siebert
Former Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs
Director of Supernus
Former partner of KPMG, LLP
Executive Vice President of Grifols, Inc.
President Global Marketing of Grifols, Inc.
Aradigm's Scientific Advisory Board is a highly
regarded team of scientific experts who help the Company with strategic
input into the development of treatments for severe respiratory disease,
and in pharmaceutical development and pulmonary drug delivery in general.
The group assists the company on a variety of issues related to potential
product applications, product development paths and clinical testing.
Peter R. Byron, Ph.D.
Medical College of Virginia,
Virginia Commonwealth University
Expertise: Aerosol Science/Pharmaceutics
Stephen J. Farr,
Expertise: Pulmonary Delivery/Pharmaceutics
Tunde Otulana , M.D.
Expertise: Pulmonary Medicine,
Adam Wanner, Ph.D.
University of Miami
Expertise: Chronic Obstructive Pulmonary Disease (COPD)
addition to this Scientific Advisory Board, the Company also engages other
scientific and medical experts to assist on issues specific to particular indications